Methods and compositions for determining lipid peroxidation levels in oxidant stress syndromes and diseases

Patent 6727075 Issued on April 27, 2004. Estimated Expiration Date:

May 31, 2021. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Abstract Claims Description Full Text

Patent References

Method and compositions to assess oxidative stress in vivo
Patent #: 5700654
Issued on: 12/23/1997
Inventor: Roberts, et al.

Method and compositions to assess oxidative stress in vivo
Patent #: 5858696
Issued on: 01/12/1999
Inventor: Roberts, II, et al.

Assessment of oxidative stress in vivo
Patent #: 5891622
Issued on: 04/06/1999
Inventor: Morrow, et al.

Method and compositions to detect autooxidation of lipids or fats ex vivo Patent #: 5945295
Issued on: 08/31/1999
Inventor: Roberts, II, et al.

Inventors

Assignee

Application

No. 09870762 filed on 05/31/2001

US Classes:

435/25, Involving oxidoreductase435/7.1Involving antigen-antibody binding, specific binding protein assay or specific ligand-receptor binding assay

Examiners

Primary: Gitomer, Ralph

Attorney, Agent or Firm

Morgan Lewis & Bockius, LLP

Foreign Patent References

WO 9404921 WO 03/01/1994

International Class

C12Q 126

Abstract

The invention includes methods useful for the diagnosis of Alzheimer's disease and the evaluation of enhanced levels of lipid peroxidation in a mammal. The methods utilize isoprostanes as sensitive and stable molecular markers for lipid peroxidation in a mammal. Methods of identifying compounds useful for the treatment of Alzheimer's disease or for reducing levels of lipid peroxidation in a mammal are also included. The invention also includes kits useful for the diagnosis of Alzheimer's disease and for the evaluation of levels of lipid peroxidation in a mammal.

Other References

Pratico, D. Increased 8, 12-iso-iPF2aVI in AD. Ann Neurol 2000:48:809-812.*
Rokach J. Isoprostanes: Chemistry and Biological Significance. Recent Res Devel in Organic Chem 1998, vol. 2, pp. 393-407.*
Mardini I. A Newly Discovered Isoprostane is a Marker of Oxidative stress in LPS Mediated Inflammation in Humans. Circulation Oct. 27, 1998, 98 (17 Sup) p. 17.*
Pratico D. Faseb J Increased F2 Isoprostanes in AD. 1998 12(15)1777-1783.*
Reilly M. Circulation. Increased Formation of Distinct F2 Isoprostanes in Hypercholesterolemia. 1998 98(25)2822-28.*
Fitzgerald G. Faseb J. Isoprostanes: Indices of Oxidant Stress. 1996 10(6)A1138.*
Pratico D. Noval Indices of Oxidant Stress in Cardiovascular Disease: Specific Analysis of F2 Isoprostanes. Prostaglandins and Control of Vascular Smooth Muscle Cell Proliferation. 1997 vol. 48, pp. 25-41.*
Arai, et al., 1995, Ann. Neurol. 38:649-652.
Arnold, et al., 1995, Am. J. Psych. 152:731-737.
Awad, et al., 1993, J. Biol. Chem. 268:4161-4169.
Balazs et al., 1994, Neurochemical Research 19:1131-1137.
Banerjee et al., 1992, Amer. Physiological Society H660-H663.
Behl, et al., 1994, Cell 77:817-827.
Busciglio, et al., 1995, Neuron. 14:879-888.
Corder, et al., 1993, Science 261:921-923.
Delanty, et al., 1997, Circulation 95:2492-2499.
Gutteridge, et al., 1990, Trends Biochem Sci. 15:129-135.
Hardy, et al., 1997, Proc. Natl. Acad. Sci. USA 94:2095-2097.
Hayn, et al., 1996, Life Sci. 59:537-544.
Hensley, et al., 1994, Proc. Natl. Acad. Sci USA 91:3270-3274.
Hwang, et al., 1994, J. Am. Chem. Soc. 116:10829-10830.
Kanai, et al., 1998, Ann Neurol. 44:17-26.
Lawson, et al., 1999, J. Biol Chem., 274:24441-24444.
Lawson, et al., 1998, J. Biol Chem. 273:29295-29301.
Li, et al., 1999, PNAS 96:13381-13386.
Lovell, et al., 1997, Neurobiol. Aging 18:457-461.
Lovell, et al., 1995, Neurology 45:1594-1601.
Lyras, et al., 1997, J. Neurochem. 68:2061-2069.
Mahley, et al., 1995, Curr. Opin. Lipidol. 6:86-91.
Mattson, et al., 1992, Neurosc. 12:376-389.
Mayeux, et al., 1993, Ann. Neurol. 34:752-754.
Meagher, et al., 1999, J. Clin. Invest. 104:805-813.
Montine et al, 1998, Ann. Neurol. 44:410-413.
Montine, et al., 1997, J. Neuropath. Exper. Neurol. 56:866-871.
Morrow, et al., 1994, J. Biol. Chem. 269:4317-4326.
Morrow, et al., 1996, Biochem, Pharmacol. 51:1-9.
Morrow, et al., 1997, Prog. Lipid Res. 36:1-22.
Nakamura, et al., 1994, Ann. Neurol 36:903-911.
Palmer, et al., 1994, Brain Res. 645:338-342.
Patrona, et al., 1997, Arterioscl. Thromb Vasc. Biol. 17:2309-2315.
Petersen, et al., 1995, JAMA 273:1274-1278.
Pratico, et al., 1995, J. Biol. Chem 270:9800-9808.
Pratico, et al., 1996, J. Biol Chem. 271:8919-8924.
Pratico, et al., 1997, J. Clin. Inv. 100:2028-2034.
Practico, et al., 1998, Nature Med. 4:1189-1192.
Practico, et al., 1999, Atheroscler, 147:1-10.
Pratico, et al., 1999, J. Neurochem. 73:736-741.
Pudukulathan, et al., 1998, J. Am. Chem. Soc. 120:11953-11961.
Reilly, et al., 1996, Circulation 94:19-25.
Reilly, et al., 1996, Circulation 94:3727 (A).
Reilly, et al., 1997, Circulation 96:3314-3320.
Rokach, et al., 1997, Prostaglandins 54:853-873.
Sayre, et al., 1997, J. Neurochem. 68:2092-2097.
Scheuner, et al., 1996, Nature Med. 2:864-870.
Schmidt, et al., 1991, Lab. Invest. 64:352-357.
Schmidt, et al., 1996, Acta Neuropathol. 91:475-481.
Selkoe, et al., 1997, Science 275:630-631.
Subbarao, et al., 1990, J. Neurochem. 55:342-345.
Takahashi, et al., 1992, J. clin. Invest. 90:136-141.
Tato, et al., 1995, J. Neurol. Neurosurg. Psychiatry 59:280-283.
Thomas, et al., 1996, Nature 380:168-171.
Turner, et al., 1996, J. Biol. Chem. 271:8966-8970.
Van Duijn, et al., 1996, J. Neurol Neurosug. Psychiatry 60:478-488.
Van Duijn, et al., 1994, Nature Genet. 7:74-78.
Wenham, et al., 1991, Lancet 337:1158-1159.
Adiyaman et al., 1998, Anal. Biochem. vol. 262, No. 1, pp. 45-56.
Practico et al., 1998, Proc. Acad. Sci., USA, vol. 95, No. 7, pp. 3449-3454.
Practico et al., 1998, FASEB Journal, vol. 12, No. 15, pp. 1777-1783.